Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma

Access Activity

Overview / Abstract:


An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, including anti-CD38 antibodies, has provided numerous therapeutic options for newly diagnosed multiple myeloma. However, the optimal selection of induction therapy and subsequent treatment sequencing for individual patients remains a challenge. Additionally, factors including age, frailty, comorbidities, transplant eligibility, treatment-related toxicities, and supportive care needs complicate treatment decisions (Costello et al, 2022). This activity chaired by Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, will explore expert guidance on current standards and new directions in newly diagnosed multiple myeloma.


Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with multiple myeloma.


Upon completion of this activity, participants should be able to:

Assess guideline-recommended treatment combination and sequencing strategies in NDMM
Evaluate the role of minimal residual disease (MRD) assessment in NDMM treatment
Review the mechanism of action, efficacy, and safety of anti-CD38 monoclonal antibodies in the treatment of NDMM
Discuss strategies to monitor and manage treatment-related toxicities and optimize survivorship care


Jul 05, 2024


Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours

1.25 CME



Presenters / Authors / Faculty

Urvi Shah, MD
Assistant Attending, Myeloma Service
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell Medical College

Sponsors / Supporters / Grant Providers

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by an educational grant from Sanofi.

Keywords / Search Terms

i3 Health i3 Health Oncology, i3 Health, CME, free CNE, Free CE, Free CME, MM, multiple myeloma, multiply relapsed, refractory, refractory multiple myeloma, therapeutics, treatment, therapies, patients, Free, CME, CE, hematologist, hematology, oncology, clinical data, therapy Free CE CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map